Compound I Formulation for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases mediated by CSF1R, c-Kit, and FLT3 lack effective formulations with improved dissolution profiles, which are essential for oral administration and therapeutic efficacy.
Innovation Solution
Compositions comprising Compound I, specifically its crystalline form (Form C) and pharmaceutically acceptable salts, combined with solubilizing agents like poloxamer 407, excipients, disintegrants, and lubricants, are developed to enhance dissolution profiles and oral bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional formulations are used, then manufacturing is simple, but dissolution profile is poor
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical parameters of the formulation system. Specifically, it changes the crystal form of Compound I from amorphous or less stable crystalline forms to the more stable Form C, and adjusts the composition ratios of excipients, disintegrants, and lubricants to optimize dissolution. This resolves the contradiction by achieving improved dissolution profiles through controlled parameter modifications while maintaining manufacturability.
Solution Approach 2:
The patent employs composite materials by combining Compound I in its specific crystal Form C with a carefully selected mixture of excipients, disintegrants, and lubricants. This composite formulation approach creates a synergistic system where the crystal form of the active compound works in conjunction with the formulation components to achieve both good dissolution profiles and ease of manufacture, resolving the technical contradiction between these two parameters.
2Ease of operation
If oral administration is implemented, then patient compliance improves, but bioavailability is limited by dissolution
Solution Approach 1:
The patent changes the dissolution parameters of Compound I by establishing a specific oral formulation containing the compound in crystal Form C with optimized excipient composition. This parameter modification enables the compound to achieve adequate dissolution in the gastrointestinal tract, thereby ensuring sufficient oral bioavailability while maintaining the convenience of oral administration.
Solution Approach 2:
The patent introduces intermediary substances (excipients, disintegrants, and lubricants) that facilitate the dissolution and absorption of Compound I in the oral route. These intermediary components act as mediators between the poorly soluble compound and the biological environment, enabling effective oral bioavailability while preserving the ease of oral administration.
3Stability of the object's composition
If crystal form stability is increased, then storage reliability improves, but dissolution rate may decrease
Solution Approach 1:
The patent optimizes the crystal form parameters by selecting Form C, which possesses an intermediate level of stability that balances storage reliability with dissolution performance. Additionally, the formulation parameters (excipient types and ratios) are adjusted to enhance the dissolution rate of this stable crystal form, thereby resolving the contradiction between stability and dissolution speed.
Solution Approach 2:
The patent creates a composite formulation where the stable crystal Form C of Compound I is combined with dissolution-enhancing excipients and disintegrants. This composite structure allows the stable crystal form to maintain its compositional integrity during storage while the formulation components work together to achieve adequate dissolution rates, resolving the contradiction between stability and dissolution speed.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions demonstrate improved dissolution profiles and therapeutic effectiveness for treating diseases mediated by CSF1R, c-Kit, and FLT3, offering enhanced bioavailability and treatment options for various conditions, including cancers and neuroinflammatory disorders.
Implementation Method 1
compositions comprising Compound I, specifically its crystalline form (Form C) and pharmaceutically acceptable salts, combined with solubilizing agents like poloxamer 407
Data Source
AI summary
Provided are compositions comprising Compound I having the following structure:or a pharmaceutically acceptable salt thereof, and a solubilizing agent; methods of making the same; and methods of using the same.